🌟We are very proud that Jennifer Schranz M.D. represented Ipsen on the EMJ GOLD Pharma Review of the year podcast!🌟 Tune in to hear Jennifer’s reflections on the trends, challenges, and opportunities shaping the rare disease landscape in 2024, and her vision for the future in 2025. 👉 https://lnkd.in/ejyfn-8r
概要
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com. Pauta exclusiva para México: Clave de Autorización COFEPRIS: 243300201B1962 CONSULTE A SU MÉDICO.
- ウェブサイト
-
http://www.ipsen.com
Ipsenの外部リンク
- 業種
- 医薬品製造業
- 会社規模
- 社員 5,001 - 10,000名
- 本社
- Boulogne Billancourt
- 種類
- 上場企業
- 専門分野
- Pharmaceuticals、Specialty care: oncology, neuroscience, endocrinology、Research: peptides, toxins、Primary Care
場所
Ipsenの社員
アップデート
-
2024 was an ✨extraordinary✨ year for all of us at Ipsen! From winning the prestigious Shingo Prize 🏆 for our Dublin site to achieving 2 simultaneous EU approvals 🌍 for rare liver disease treatments and FDA breakthroughs 💊 in pancreatic cancer and PBC, innovation led the way. We celebrated diversity 🌟 with women holding 54.6% of managerial roles and achieved 9.2% YTD sustainable growth 📊, supported by a record 61 points 📈 in the S&P Sustainability Assessment. Our pipeline 🔬 expanded with up to 8 new assets added in 2024. Ranked #25 in Fortune’s Best 100 Companies in Europe 🏅 and earning Great Place to Work certification 🌟 in 28 countries, Ipsen is ready to shine even brighter in 2025! ✨
-
We’re proud to share an insightful conversation between Sandra Silvestri, MD, PhD, EVP and Chief Medical Officer, Ipsen, and Robert Mitchell-Thain, CEO of the PBC Foundation Sandra and Robert discuss how to feel empowered whilst living with #PrimaryBiliaryCholangitis (PBC), the importance of knowledge and the impact of honest communication. Read the full article here and learn more about #ThisismyPBC
Executive Vice President & Chief Medical Officer, Head of Global Medical Affairs, Global Patient Safety and Global Patient Affairs, ExComm member @ Ipsen, Board Member @ Genfit
I recently had the pleasure of speaking with Robert Mitchell-Thain, CEO of the @PBCFoundation, about the importance of dispelling myths and empowering people with #PrimaryBiliaryCholangitis (PBC) to find their voice and talk about their symptoms with their doctor. I’m also very excited to introduce #ThisismyPBC, an Ipsen disease awareness campaign that is focused on empowering individuals to take charge of their unique PBC journey. Read more here!
Opening the door to Primary Biliary Cholangitis (PBC) conversations, with Robert Mitchell-Thain
Sandra Silvestri, MD, PhD (LinkedInより)
-
Ipsen announces global licensing agreement with Biomunex, adding a new pre-clinical T cell engager (TCE) to our growing TCE portfolio. Learn more: https://lnkd.in/eqPcMTTV
-
-
#PrimaryBiliaryCholangitis (PBC) is a rare liver disease, that affects the liver’s bile ducts, which can eventually lead to liver failure if left untreated. During #TLM24, we spoke with Dr. Kris Kowdley about the importance of managing disease progression. Watch the video to learn more:
-
As #TLM24 comes to a close it is great to reflect on all of the discussions we have been having with liver experts, doctors, patients and carers. Interest in #RareLiverDisease is clearly growing and progressing the collective understanding of the management of #PBC, #PFIC and #ALGS. A common theme is the need to diagnose early, listen to and treat each patient individually, including considering daily life impact. Dr. Mark Swain shares his thoughts on daily life with #PBC.
-
Reflecting on the #WorldOrphanDrugCongress, we are inspired by the powerful perspectives shared by individuals living with rare diseases. Their stories emphasize our mission to improve lives through innovation and compassion. Read more from our Head of Global Public Affairs & Advocacy Jan Swiderski on themes that emerged from the congress, including the vital need to amplify patient perspectives, foster collaboration among stakeholders, and ensure timely access to medicines. At Ipsen, we are committed to working with all stakeholders to continue evolving our policies to support and address the needs of people living with rare diseases. #RareDisease #Ipsen
Championing Patient Voices: Insights from the World Orphan Drug Congress 2024
World Orphan Drug Congress Europe (LinkedInより)
-
At Ipsen, we are committed to fostering a #culture of collaboration, excellence and impact, where we can all be our true selves and thrive. Learn more about our culture and join us to create real impact for patients and society! 👉 https://lnkd.in/ea6-S8hC
-
Listen to Tim’s story on his experience of being diagnosed with prostate cancer Receiving a prostate cancer diagnosis can be an isolating and frightening experience. Ipsen’s “Get Men Talking” podcast encourages men to have a more open dialogue about prostate cancer and screening. Hear as Tim Batchelor, Head of Global Commercial Learning and Development at Ipsen, shares his story: https://lnkd.in/drB2yi3k